Lupus & antiphospholipid syndrome
Hydroxychloroquine and Pre‐eclampsia in a Diverse Cohort of Women With Systemic Lupus Erythematosus
Authors' conclusion
Although this study found no reduced risk of HCQ on pre-eclampsia or eclampsia, residual confounding may be attenuating the effect despite an integrated health care delivery system setting with detailed clinical data.
Study context
- Population
- Pregnant patients with prevalent systemic lupus erythematosus (SLE) at Kaiser Permanente Northern California, 2011–2020
- Participants
- 324 patients399 pregnancies
- Exposure
- Hydroxychloroquine (HCQ) treatment in early pregnancy vs no HCQ treatment
- Outcome
- Pre-eclampsia or eclampsia
Methodological detailspropensity score-adjusted, modified Poisson models, stratified analysis for effect modification
- Propensity score-adjusted
- Modified Poisson models
- Stratified analysis for effect modification
Main finding
As reported in the abstract
- Null association between HCQ and pre-eclampsia or eclampsia, consistently across multiple exposure definitions
Observational data: associations, not effects.
Further findings
Pre-eclampsia or eclampsia in nullipara patients (subgroup)
- Risk ratios (RRs) consistently lower among nullipara patients
Pre-eclampsia or eclampsia in high-risk subgroup (history of nephritis, aPL positivity, or pregestational hypertension)
- RRs consistently protective but not statistically significant (for both nullipara and multipara patients)
Original publication
Hydroxychloroquine and Pre‐eclampsia in a Diverse Cohort of Women With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). Published 9 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →